biomedica life sciences sa
DESCRIPTION
BIOMEDICA LIFE SCIENCES SA. Expanding a commercial SME specializing in radiopharmaceutic al s and high-tech medical imaging instrumentation into a dynamic group of Biotechnology companies. - PowerPoint PPT PresentationTRANSCRIPT
BIOMEDICA BIOMEDICA LIFE SCIENCES SALIFE SCIENCES SA
Expanding a commercial SME specializing in radiopharmaceuticals and
high-tech medical imaging instrumentation into a dynamic group of Biotechnology companies
BIOMEDICA LIFE SCIENCES SABIOMEDICA LIFE SCIENCES SAEstablished in 1994Total number of employees: 29 2003 revenue from sales 4,016 mil € EBT 0,9 mil €
Coupling BIOMEDICA’s management and marketing resources and expertise
withexcellence in biotechnological research
of Greek Research Institutes and University Laboratories
Main concept for the expansion:
Strategy Main Points and ObjectivesStrategy Main Points and Objectives
1. Establishing the company’s R&D base through the collaboration with research groups in National Research Centres and Universities
2. Organizing and managing a state-of-the-art Radiopharmaceuticals Production Unit (GMP) based on the infrastructure and know-how of NCSR “Demokritos”
3. Designing, conducting and funding of multicenter clinical trials in Greece and abroad
4. Expanding into Molecular Diagnostics & Genetic Testing
1.1. Establishing the R&D BaseEstablishing the R&D BaseCollaborating with the Greek Research Community I. Direct funding of novel research ideas in Radiopharmacy and Radiodiagnostics
1. Radiolabeled Biomolecules in Diagnosis and TherapyTc99m labelled bombesin, minigastrin and neurotensin analogues Principal Investigators: A. Varvarigou, NCSR “Demokritos”
T. Maina, B. Nock, NCSR “Demokritos” Greek patents granted – European patents pending
Tc99m labelled YIGSR for radiodiagnosis & immunotherapy Principal Investigator:G. Koliakos, University of Thessalonica
Greek patent granted – European patent granted
2. Peptide Design and Synthesis Principal Investigator: P. Cordopatis, University of Patras
Greek patents granted – European patents pending
II. Participating as co-sponsor and/or end-user in II. Participating as co-sponsor and/or end-user in selected research programs funded by GSRT andselected research programs funded by GSRT and EUEU
EKBAN 2003-2006 «Τεχνητά Χρωμοσώματα Εντομοιών (ΤΕΧΠΕΝ) και Τεχνολογίες για Γονιδιακή Θεραπεία και Συνεχή Υψηλού Επιπέδου Έκφραση Θεραπευτικών Πρωτεϊνών σε εντομικά Συστήματα Παραγωγής», ΕΚΕΦΕ «Δημόκριτος», Ινστιτούτο Pasteur, Biomedica, 582.000 € (budget of project, Biomedica participation 245.000 €)
ΗΡΩΝ 2003-2006 «Ανάπτυξη και αξιολόγηση ραδιοεπισημασμένων βιομορίων για διάγνωση ή/και θεραπεία νεοπλασιών διαφόρων μορφών» Biomedica, 264.000 € (granted by 50%)
ΠΕΝΕΔ – ΔΙΑΚΡΑΤΙΚΕΣ ΣΥΝΕΡΓΑΣΙΕΣ
Biomedica Biomedica Research PersonnelResearch Personnel
May 2004BIOMEDICA Funded Research Programs:7 full time positions – 4 PhDs
Co-Sponsored Research Programs:5 full time positions – 4 PhDs
2. Organizing and Managing 2. Organizing and Managing a a Radiopharmaceutical Production UnitRadiopharmaceutical Production Unit
A strategic alliance between BIOMEDICA and the Institute of Radioisotopes &
Radiodiagnostic Products has been approved by the Board of Directors of NCSR
“Demokritos” in May 2004
Joint Venture Organization and Management of the Institute’s
unique Infrastructure
Implementation of Good Manufacturing Practice (GMP) Protocols
Production of selected highly demanded radiopharmaceuticals in Greece and abroad
Pilot production of novel products for clinical trials Providing specialized GMP lyophilization services to
third parties Providing education and training
NCSR “Demokritos” InfrastNCSR “Demokritos” Infrastrructureucture
Class 100 lyophilization clean room Class 100 lyophilization clean room Radiochemical – Radiobiological Quality Control Labs Radiochemical – Radiobiological Quality Control Labs Hot-CellsHot-Cells
A joint A joint BIOMEDICABIOMEDICA & & NCSR “Demokritos”NCSR “Demokritos” team will team will carry out development, carry out development, production and QC of production and QC of
radiopharmaceuticalsradiopharmaceuticals
4. Expanding into Molecular Diagnostics & 4. Expanding into Molecular Diagnostics & Genetic TestingGenetic Testing
BioGenomica S.ABioGenomica S.A. Centre for Genetic Testing and Analyses
A spin-off Company of NCSR “Demokritos” established in February 2004
The company’s business plan has been successfully incorporated in the PRAXE Phase B Program of GSRT with a total budget of 2 mil €.
BioGenomicaBioGenomica SA SACentre for Genetic Testing and Analysesa spin-off company of NCSR “Demokritos”
Genetic testing for predisposition to hereditary diseasesCancer -Neurological and Psychiatric Disorders - Rare Diseases
DNA sequencing tailoring specific laboratory needsFood industry – Public health
Providing services to hospitals, clinics and diagnostic centres in Greece and abroad
Participation in international genetic testing networks
Providing services to the food and agricultural industry
June 2004:total number of employees: 6 (3 PhDs)
State-of-the-art instrumentation: Automated DNA Sequencing, dHPLC, Real-time PCR and DNA microarray-based technologies
European Molecular Quality Network evaluation and accreditation
BioGenomica ResearchBioGenomica Research
Establishment of International Scientific Advisory Board Design of clinical research protocols jointly with medical
centers and collaborative groups and networks
Participation in large-scale genetic epidemiology studies
Incubation of basic science, biochemical and biophysical research projects jointly with Universities and Research Institutes